Medical Doctor Program year 2020 Reported 2019–2020 Source: CMS Open Payments, 2026 publication

Kalpana Cheeti

Geriatric Medicine Hackensack, NJ Medical Doctor

NPI 1649352857 CMS profile 255857

15 Anderson St, Hackensack, NJ 07601

Open in the dashboard

General payments

$2,336

180 records reported · program years 2019–2020

Research payments

$0

Paid to them · None reported · program years 2019–2020

Ownership & investment interest

$0

None reported

Through program year 2020, Kalpana Cheeti of Hackensack, NJ is reported in the CMS Open Payments database as having received $2,336 across 180 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Geriatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2020 General $391 28
2019 General $1,945 152

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kalpana Cheeti
  • Geriatric Medicine median
  • Middle half of Geriatric Medicine
  • National median

In program year 2025, general payments to Kalpana Cheeti were reported at $0. Among 1,028 Geriatric Medicine profiles paid that year, the median was $123 and the middle half received between $35 and $408.

Show as a table
Year Kalpana Cheeti Geriatric Medicine median Middle half National median
2019 $1,945 $122 $40–$435 $163
2020 $391 $98 $25–$349 $114
2021 $0 $125 $34–$441 $132
2022 $0 $124 $36–$408 $149
2023 $0 $121 $41–$383 $160
2024 $0 $134 $41–$435 $164
2025 $0 $123 $35–$408 $169

Breakdown

Who paid General payments · program years 2019–2020
  1. Novo Nordisk Inc $303 24 payments
  2. Janssen Pharmaceuticals, Inc $220 16 payments
  3. Amgen Inc. $216 17 payments
  4. Lilly USA, LLC $195 14 payments
  5. Merck Sharp & Dohme Corporation $191 14 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $188 14 payments
  7. Pfizer Inc. $185 13 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $176 13 payments
  9. Amarin Pharma Inc. $151 18 payments
  10. Arbor Pharmaceuticals, Inc. $100 7 payments
  11. Other $412 30 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2020
  1. Food and Beverage $2,230 165 payments
  2. Education $77 13 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $29 2 payments
Products named General payments · program years 2019–2020
  1. Ozempic $215 16 payments
  2. INVOKANA $214 15 payments
  3. XARELTO $205 15 payments
  4. XIFAXAN $176 13 payments
  5. TRULICITY $168 12 payments
  6. JANUVIA $166 12 payments
  7. JARDIANCE $159 11 payments
  8. Repatha $156 12 payments
  9. STEGLATRO $153 11 payments
  10. Vascepa $138 17 payments
  11. Other $1,711 132 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 50 drugs

Part D claims

2,527

Median for Internal Medicine: 777

Drug cost

$74,375

Median for Internal Medicine: $73,373

Branded share of claims

9.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Januvia Sitagliptin Phosphate Brand 14 $14,891
Eliquis Apixaban Brand 21 $11,790
Xarelto Rivaroxaban Brand 12 $8,721
Livalo Pitavastatin Calcium Brand 14 $6,363
Pitavastatin Calcium Generic 14 $4,916
Atorvastatin Calcium Generic 294 $3,108
Rosuvastatin Calcium Generic 177 $2,791
Amlodipine Besylate Generic 240 $1,771
Levothyroxine Sodium Generic 174 $1,575
Escitalopram Oxalate Generic 111 $1,295

The 10 drugs with the highest cost, of 50 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$69,573

Medicare's payments for the services billed

Medicare patients

358

Average age 76

Services billed

1,689

267 women, 91 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Ischemic heart disease 30%
Diabetes 26%
Osteoporosis 25%
Heart failure 23%
Cancer 20%
Depression 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

180 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2020

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record